Abstract
The presence of Galanin and Neuropeptide Y and/or their receptors in several areas of the brain involved in memory, mood, cardiovascular control and food intake indicates that Galanin, and Neuropeptide Y could equilibrate the physiological actions of each other. There is evidence for the existence of interactions between Galanin Receptor and Neuropeptide Y Receptor in the nucleus of the solitarii tract (NTS), hypothalamus and dorsal raphe nucleus probably taking place with the formation of heteromers between Galanin Receptor and Neuropeptide Y Y1 Receptor. The galanin fragment (Gal 1-15) preferring receptors may instead be formed by the GalR1-GalR2 heteromer which in the NTS may interact with Neuropeptide Y Y2 receptors. These receptor heteromers may be one key molecular mechanism for Galanin and its N-terminal fragment (Galanin 1-15) to modulate the function of different types of glia–neuronal networks in the CNS, especially the emotional, metabolic and cardiovascular networks.
Keywords: Galanin, Galanin 1-15, Galanin receptor subtypes, GPCRs, Heteromers, Neuropeptide Y, NPY receptors.
Current Protein & Peptide Science
Title:Galanin Receptor/Neuropeptide Y Receptor Interactions in the Central Nervous System
Volume: 15 Issue: 7
Author(s): Zaida Diaz-Cabiale, Antonio Flores-Burgess, Concepcion Parrado, Manuel Narvaez, Carmelo Millon, Araceli Puigcerver, Rafael Covenas, Kjell Fuxe and Jose A. Narvaez
Affiliation:
Keywords: Galanin, Galanin 1-15, Galanin receptor subtypes, GPCRs, Heteromers, Neuropeptide Y, NPY receptors.
Abstract: The presence of Galanin and Neuropeptide Y and/or their receptors in several areas of the brain involved in memory, mood, cardiovascular control and food intake indicates that Galanin, and Neuropeptide Y could equilibrate the physiological actions of each other. There is evidence for the existence of interactions between Galanin Receptor and Neuropeptide Y Receptor in the nucleus of the solitarii tract (NTS), hypothalamus and dorsal raphe nucleus probably taking place with the formation of heteromers between Galanin Receptor and Neuropeptide Y Y1 Receptor. The galanin fragment (Gal 1-15) preferring receptors may instead be formed by the GalR1-GalR2 heteromer which in the NTS may interact with Neuropeptide Y Y2 receptors. These receptor heteromers may be one key molecular mechanism for Galanin and its N-terminal fragment (Galanin 1-15) to modulate the function of different types of glia–neuronal networks in the CNS, especially the emotional, metabolic and cardiovascular networks.
Export Options
About this article
Cite this article as:
Diaz-Cabiale Zaida, Flores-Burgess Antonio, Parrado Concepcion, Narvaez Manuel, Millon Carmelo, Puigcerver Araceli, Covenas Rafael, Fuxe Kjell and Narvaez A. Jose, Galanin Receptor/Neuropeptide Y Receptor Interactions in the Central Nervous System, Current Protein & Peptide Science 2014; 15 (7) . https://dx.doi.org/10.2174/1389203715666140901111709
DOI https://dx.doi.org/10.2174/1389203715666140901111709 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial [Hot Topic: Gender Differences in Cardiovascular Diseases. A Need for Action (Executive Guest Editors: Giuseppe Barbaro and Giuseppe M.C. Rosano)]
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Drug Discovery Technologies Polymeric Nanoparticles for Ophthalmic Drug Delivery: An Update on Research and Patenting Activity
Recent Patents on Nanomedicine Reading and Writing the Blood-Brain Barrier: Relevance to Therapeutics
Recent Patents on CNS Drug Discovery (Discontinued) Atrial Fibrillation During or After TAVI: Incidence, Implications and Therapeutical Considerations
Current Pharmaceutical Design Renin--Angiotensin System Gene Polymorphism and Regression of Left Ventricular Hypertrophy in Hypertension
Current Pharmacogenomics Advances in Nanomedicine Towards Clinical Application in Oncology and Immunology
Current Pharmaceutical Biotechnology Pathophysiological Role of Proteasome-Dependent Proteolytic Pathway in Endothelin-1-Related Cardiovascular Diseases
Current Vascular Pharmacology An Update in the Management of Obesity: The Weight of CNS Targets
Recent Patents on CNS Drug Discovery (Discontinued) Digital Ulcers in Systemic Sclerosis – Frequency, Subtype Distribution and Clinical Outcome
Current Rheumatology Reviews Angiotensin II: Role in Skeletal Muscle Atrophy
Current Protein & Peptide Science Formulation of Gastric Floating System Using Bio-Sourced Terminalia Catappa Gum and in vivo Evaluation
Current Drug Delivery Carbon Monoxide and the Brain: Time to Rethink the Dogma
Current Pharmaceutical Design Ambulatory Blood Pressure Monitoring in Type 2 Diabetes Mellitus: A Cross-sectional Study
Current Hypertension Reviews Determinants of the Resolution of Type 2 Diabetes After Bariatric Surgery
Vascular Disease Prevention (Discontinued) The Effect of Acute Hypoxia on Excitability in the Heart and the L-Type Calcium Channel as a Therapeutic Target
Current Drug Discovery Technologies Teratological Consequences of Nitric Oxide Synthesis Inhibition
Current Pharmaceutical Design Understanding the Concept of Chronotherapeutics in the Management of Diabetes Mellitus
Current Diabetes Reviews Hereditary Haemorrhagic Teleangiectasia: Diagnostic Imaging of Visceral Involvement
Current Pharmaceutical Design Elevated Heart Rate, A Risk Factor and Risk Marker of Cardiovascular Disease
Current Hypertension Reviews